NAD+ precursor fact sheet
Nicotinamide mononucleotide
Also known as NMN, beta-NMN
NMN is a biochemical step on the pathway toward NAD+. Early trials report target engagement and scattered functional signals, but not proof of slowed aging or disease prevention.
Quick answer
NMN can affect NAD-related biomarkers in small human trials, but it is not an FDA-approved drug for anti-aging, energy, sleep, muscle performance, or metabolic disease. The clinical significance of reported signals remains uncertain.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Nicotinamide mononucleotide?
NMN is a naturally occurring nucleotide derivative used by cells to produce NAD+.
It is related to, but not interchangeable with, nicotinamide riboside or NAD+ itself.
Why are people interested in it?
Animal studies made NMN prominent in healthy-aging research, and small human trials have since examined metabolic, walking, sleep, and body-composition endpoints.
Most studies are short, use modest sample sizes, and measure many outcomes, so replication and clinical relevance matter.
Current regulatory status
NMN has no FDA-approved drug indication for aging or any consumer wellness goal. Product-specific U.S. marketing status is a separate legal question from whether a health claim is clinically proven.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
Human randomized trials are emerging and show biochemical effects, but results for walking, strength, insulin sensitivity, sleep, and other functional outcomes are not yet consistent enough for broad claims.
Potential benefits being researched
- Small trials report increased NAD-related metabolites and some secondary signals in physical function or sleep.
- A controlled trial of a pharmaceutical NMN formulation found target engagement but did not establish a broad physiological rejuvenation effect.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Short studies cannot rule out uncommon or long-latency harms.
- Commercial products may not match the identity, purity, or stability of material used in a clinical trial.
- The implications of long-term NAD-pathway manipulation in cancer, inflammatory disease, or other conditions are unresolved.
What we still do not know
- Whether any signal replicates in larger and more diverse populations
- Whether changes in biomarkers translate into fewer diseases or better function
- Long-term safety
- Which observed differences reflect NMN rather than chance across many measured endpoints
Plain-English takeaway
NMN is a real research molecule with early human data. It is not yet a proven anti-aging, sleep, metabolic, or performance intervention.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1Randomized NMN trial in older adults
Controlled study of walking, sleep, and related endpoints that requires replication and cautious interpretation.
- 2Randomized trial of the NMN formulation MIB-626
Human target-engagement and physiological-outcomes trial in adults with overweight or obesity.
- 3Clinical trial of NMN in healthy adults
Small placebo-controlled study assessing short-term safety and selected outcomes.
- 4FDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.